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Background: Expression of the non-receptor tyrosine kinase ETK/BMX has been reported in several solid tumors,
but the underlying molecular mechanisms and its clinical significance in renal cell carcinoma (RCC) remain to be
elucidated.
Methods: ETK expression in 90 human RCC and 30 human normal renal tissue samples was examined by
immunohistochemistry and compared with several clinicopathologic parameters. To further demonstrate the
biological function of ETK in RCC, Western blot was used to test the expression level of ETK protein in RCC cell
lines. Subsequent to the downregulation of ETK by small interfering RNA, the effects of ETK on RCC cell growth,
apoptosis, migration and invasion were assessed by methyl thiazol tetrazolium assay, flow cytometry and transwell
assay. And the varying expression of VEGF, STAT3 and phosphorylated STAT3 (p-STAT3) in RCC were evaluated by
Western blot.
Results: Immunohistochemistry analysis showed that ETK expression was highly increased in RCC and was
positively correlated with clinical stage, grade and metastasis. Simultaneously, the overall survival time in patients
with higher ETK expression was obviously shorter than that in patients with lower ETK expression. ETK was also
detected in RCC cell lines. Moreover, the down-regulating ETK significantly inhibited RCC cell growth, migration,
invasion and promoted apoptosis. The expression of VEGF and p-STAT3 were also decreased.
Conclusions: Our study suggests that the overexpression of ETK is associated with the malignancy and disease
progression of RCC. Since ETK is also involved in RCC cell biological function and VEGF-ETK-STAT3 loop, ETK may be
used as a potential therapeutic target for RCC.
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RCC is one of the most common malignant tumors in
urology. RCC accounts for 2-3% of all malignant tumors
in adults, afflicts about 209,000 people, and causes
102,000 deaths per year worldwide. The incidence and
mortality rate of RCC have increased over the past sev-
eral years [1,2]. RCC is classified into five major sub-
types: clear cell (the most common type, which accounts
for 82%), papillary, chromophobe, collecting duct and
unclassified RCC. Many renal masses remain asymptom-
atic and nonpalpable until the late stages of the disease.* Correspondence: qiushp@mail.sysu.edu.cn
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unless otherwise stated.Curative nephrectomy is the first treatment choice for
RCC. However, metastatic disease recurs in a third of
these patients. Still, About 30% of patients already have
metastasis at the time of diagnosis [3]. Although several
promising biomarkers for RCC such as Carbonic anhy-
drase IX, B7-H1 and P53 have been investigated, none
have been validated [4,5]. RCC is resistant to chemo-
therapy, radiotherapy and immunotherapy. Although
several targeted therapies, such as multitargeted tyro-
sine kinase inhibitors (TKIs) and Temsirolimus, which
target the VHL-HIF-VEGF and/or mTOR pathways,
have been approved for the treatment of advanced
RCC, complete responses are rare and resistance ultim-
ately will occur after a few months or a few years [6].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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peutic targets for RCC are urgently needed.
Epithelial and endothelial tyrosine kinase (ETK), also
known as bone marrow X kinase (BMX), is one member
of the Tec family of non-receptor tyrosine kinases. ETK
contains a PH (pleckstrin homology) domain, a SH3
(SRC homology 3) domain, a SH2 (SRC homology 2) do-
main from the amino terminus, and the kinase domain
in the carboxyl terminus [7,8]. ETK is expressed in epi-
thelial cells and distributed in lympho-haematopoietic
cells [9]. ETK can be activated by several extracellular
stimuli, including growth factors, cytokines, extracellular
matrix and hormones [10]. ETK is a major regulatory
molecule in various cell signal pathways, and therefore
plays an important role in the initiation, transformation,
progression and metastasis of cancer [11,12]. It has been
proven that ETK is a critical mediator of Src-induced
cell transformation and STAT3 activation. Src-ETK-
STAT3 is an important pathway in cellular transform-
ation [13]. However the expression and role of ETK in
renal cell carcinoma still remain unclear.
In the present study, we demonstrated that ETK ex-
pression was upregulated in RCC tissue samples and cell
lines. The overexpression of ETK was correlated with
clinical stage, tumor grade, metastasis and survival time.
Furthermore, ETK regulated cell proliferation, apoptosis,
migration, and invasion of RCC. Our results suggest that
ETK is a potential prognostic factor and may serve as a
drug therapeutic target for RCC.
Methods
Tissue microarrays
Our tissue microarrays contain 90 specimens of RCC and
30 specimens of paracancerous normal renal tissues from
the First Affiliated Hospital of Sun Yat-sen University
(Guangzhou, China) between January 2005 and November
2011. All RCC patients were treated by radical nephrec-
tomy. All samples were histologically confirmed. Among
90 RCC patients, there were 55 male and 35 female at
a mean age of 55.2 years (ranging from 19 to 80 years).
Tumors were staged according to the 2009 TNM staging
system [14] and graded according to the criteria of
the World Health Organization [15,16]. The Medical
Ethics Committee of Sun Yat-sen University approved this
study’s protocol.
Cell culture
Five human RCC cell lines 786-O, 769-P, A-498, ACHN,
OS-RC-2 and a normal renal proximal tubular cell line
HK-2 were used in this study. 786-O, 769-P, ACHN and
OS-RC-2 were purchased from the Cell Bank of the
Chinese Academy of Sciences. A-498 and HK-2 were
conserved in the lab of Research Center for Clinical La-
boratory Standard of Sun Yat-sen University. 786-O,769-P and OS-RC-2 were cultured in RPMI-1640
(Gibco, USA); A-498, ACHN and HK-2 were maintained
in DMEM (Gibco, USA) containing 10% fetal bovine
serum (Gibco, USA) at 37°C in a 5% CO2 atmosphere.
Immunohistochemistry and evaluation of ETK expression
Tissue microarrays were deparaffinized with xylene and
rehydrated through graded alcohol washes, followed by
antigen retrieval by heating sections in sodium citrate
buffer (10 mM, pH 6.0) for 10 min. The sections were
incubated with 3% hydrogen peroxide for 10 min to
block endogenous peroxidase activity at room temperature.
Nonspecific reactions were blocked by incubating the sec-
tions in a solution containing normal goat serum (dilution
1:10). Then the slides were incubated with a 1:100 dilution
of monoclonal mouse IgG anti-ETK antibody (BD, USA)
at 4°C overnight. Following washing with PBS, slides were
incubated with biotinylated secondary antibodies and
avidin-biotin peroxidase complex (Dako Inc.) for 30 min.
Reaction products were visualized by 3,3′-diaminobenzi-
dine (DAB) and then counterstained with hematoxylin.
The negative control was prepared by replacing the pri-
mary antibody with a primary antibody dilution buffer.
Using a microscope, two independent pathologists ob-
served the distribution, staining intensity and positive ra-
tio of ETK expression. The ETK immunohistochemical
staining was classified as follows [17,18]: no staining
scored 0; faint or moderate staining in ≤ 25% of tumor
cells scored 1; moderate or strong staining in 25% to
50% of tumor cells scored 2; strong staining in ≥ 50% of
tumor cells scored 3. For each sample, 4 randomly se-
lected areas were observed under high magnification
and 100 tumor cells in each area were counted to calcu-
late the proportion of positive cells. Positively high ex-
pression of ETK was defined as staining index ≥ 2. Low
expression of ETK was defined as staining index<2,
accordingly.
Western blot analysis
The expression of ETK in 786-O, 769-P, A-498, ACHN,
OS-RC-2 and HK-2 cells was detected by Western blot
as described previously [19]. Briefly, total proteins were
extracted from RCC cell lines and denatured in a so-
dium dodecyl sulfate (SDS) sample buffer, then equally
loaded onto 10% polyacrylamide gel. After electrophor-
esis, the proteins were transferred to a polyvinylidene
difluoride membrane. Blots were incubated with the
indicated primary antibodies overnight at 4°C and de-
tected with horseradish peroxidase-conjugated second-
ary antibody (dilution 1:10,000, Abcam, USA). The
mouse monoclonal anti-ETK antibody (BD, USA), the
rabbit monoclonal anti-STAT3 antibody (Abcam, USA),
the rabbit monoclonal anti-phospho-STAT3 antibody
(Abcam, USA) and the rabbit monoclonal anti-VEGF
Zhuang et al. Journal of Experimental & Clinical Cancer Research 2014, 33:25 Page 3 of 8
http://www.jeccr.com/content/33/1/25antibody (Abcam, USA) were used at the dilution of
1:1,000, whereas anti-β-actin (Santa Cruz, USA) was
used at the dilution of 1:2,000.
RNA interference (RNAi) to knockdown ETK
We chose two typical clear cell RCC cell lines 786-O
and 769-P for further study. As described in the litera-
ture [20,21], 786-O and 769-P cells were transfected
with small interfering RNA (siRNA) against ETK and
negative control siRNA by Lipofectamine 2000 and
Opti-MEM I (Gibco, USA) according to the manufac-
turer’s protocol. All siRNAs were purchased from Ribo-
Bio Co. China, siRNA concentrations were 100 nM.
Briefly, 1 × 105 cells were plated in each well of 6-well
plates and cultured to reach a 80% confluence. Cells
were then transfected with siRNA by using the transfec-
tion reagent in serum-free medium. Total RNA and
protein were isolated at 48 h after transfection. ETK ex-
pression was monitored by real-time reverse transcription-
polymerase chain reaction (RT-PCR) and Western blot, as
mentioned above.
Real-time reverse transcription-polymerase chain reaction
For real-time RT-PCR, total RNA was isolated from
786-O and 769-P cells transfected with ETK siRNA or
control siRNA using Trizol Reagent (Invitrogen, USA)
as the manufacturer’s protocol required, and subjected
to reverse transcription in 20 μl using reverse transcript-
ase of First Strand cDNA Synthesis Kit (Invitrogen,
USA). RNA concentrations were 1–5 μg/μl. Then ampli-
fication was carried out in a total volume of 25 μl using
SYBR Premix Ex Taq Kit (ABI, USA). The sequences of
ETK primers were as follows: forward, 5′-GAGCCGA
AGTCAGTGGTTGA-3′; reverse, 5′-ACTTCCCGTCC
ACGAAGAAC-3′. The sequences of internal control
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were as follows: forward, 5′-TGTTCGTCATGGGTGT-
GAAC-3′; reverse, 5′-ATGGCATGGACTGTGGTCAT-
3′. All PCR were performed in triplicate.
Cell proliferation assay
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assays were performed by the following
well-established method. In a 96-well plate, 1.0 × 104
cells were plated in each well. The cells were incubated
for 48 h. MTT was dissolved in phosphate-buffered sa-
line (5 mg/ml) and filter-sterilized. Before the incuba-
tion, 20 μl of MTT solution was added to each well. The
plate was incubated in an incubator at 37°C for 4 h.
Media were aspirated gently, and 150 μl of dimethyl sulf-
oxide (DMSO) was added to each well to dissolve forma-
zan crystals. The absorbance was measured at 490 nm.
All experiments were performed in triplicate, and the
cell proliferation was tested using the absorbance.Flow cytometry analysis for apoptosis
Detection of apoptosis by flow cytometry was performed
using the Annexin V-FITC/PI Apoptosis Detection Kit
(Roche, Switzerland). The transfected cells were harvested
with trypsinization (no Ethylene Diamine Tetraacetic
Acid, EDTA containing). Staining was performed accord-
ing to the producer’s manual. Flow cytometry (BD, USA)
was performed immediately.
Migration and invasion assay
Cell migration and invasion were assessed using the 24
well-plate transwell insert (BD, USA) according to the
manufacturer’s instructions. For cell migration, a trans-
well insert without matrigel was used; while for cell inva-
sion, the transwell filters were pre-coated with matrigel
[22]. In brief, 500 μl of prepared serum-free suspension
of transfected cells with ETK siRNA or negative control
siRNA (1 × 105 cells/ml) was added into the interior of
each insert (8 μm pore size); 500 μl of medium contain-
ing 10% fetal bovine serum was added to the lower
chamber of the insert. Cells were incubated at 37°C in a
5% CO2 atmosphere for 36 h to 48 h. Then, non-
invading cells in the interior of the insert were gently re-
moved with a cotton-tipped swab; invasive cells on the
lower surface of the inserts were stained with the stain-
ing solution for 20 min and counted under a micro-
scope. All experiments were performed in triplicate.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 soft-
ware. The relationship between ETK expression and the
clinicopathologic features of RCC was assessed by chi-
square test or Fisher’s exact test. Continuous data was
analyzed by t-test or one-way analysis of variance
(ANOVA) followed by Bonferroni’s post-hoc test. Survival
curves were plotted using the Kaplan-Meier method and
compared with the log-rank test. P value of less than 0.05
was considered statistically significant.
Results
ETK overexpression in RCC tissues and its relationship
with the clinicopathological parameters
Immunochemical staining tests showed that ETK pro-
tein was mostly located in the cytoplasm as yellow-
to-brown staining in the RCC tissues. ETK expression
was weak in normal renal tissues, but stronger staining
was observed in RCC tissues (Figure 1). As shown in
Table 1, ETK protein was highly expressed in 56 of 90
(62.2%) primary RCC, while only expressed in 2 of 30
(6.7%) normal tissues. The difference was statistically
significant (P<0.001). Furthermore, ETK expression was
significantly correlated with clinical staging (P = 0.005),
pathological grade (P = 0.001) and metastasis (P = 0.002).
However, it was not associated with age (P = 0.788),
Figure 1 Immunohistochemical staining of ETK protein in tissue microarray. A Minimal expression of ETK in paracancerous normal renal
tissue (×400), B Low expression of ETK in paracancerous normal renal tissue (×400), C High expression of ETK in RCC tissue (×400).
Zhuang et al. Journal of Experimental & Clinical Cancer Research 2014, 33:25 Page 4 of 8
http://www.jeccr.com/content/33/1/25gender (P = 0.322) or position of the tumor (P = 0.351).
Taken together, these observations showed that high
level of ETK expression were closely associated with the
clinical progession of RCC.
Correlation of ETK expression with overall survival
Clinical outcome analysis was performed on all of the 90
RCC patients underwent radical nephrectomy who wereTable 1 Correlation between ETK expression and the
clinicopathological parameters of RCC









Normal renal tissus 30 2 28 <0.001
RCC tissues 90 56 34
Age (years) 0.788
≤50 28 16 12
50~70 50 32 18
≥70 12 8 4
Gender 0.322
Male 55 32 23
Female 35 24 11
Position of the tumor 0.351
Upper pole 36 20 16
Central part 19 11 8
Lower pole 35 25 10
TNM stage 0.005
I + II 67 36 31
III + IV 23 20 3
Grade (Differentiation level) 0.001
Well 66 34 32
Moderately and poorly 24 22 2
Metastasis 0.002
No 72 39 33
Yes 18 17 1followed up for a median of 49.6 months. There were 56
tumors (62.2%) with high expression (ETK staining
index ≥ 2) and 34 tumors (37.8%) with low expression
(ETK staining index<2). Kaplan-Meier survival analysis
indicated higher levels of ETK expression were associ-
ated with shorter survival time. Moreover, the log-rank
test showed that overall survival was significantly differ-
ent between the low and high ETK expression groups
(P<0.05). As shown in Figure 2, the cumulative 5-year
survival rate was 83.2% in the low-ETK-expression
group, and 65.5% in the high-ETK-expression group.
Upregulation of ETK in RCC cell lines
We detected the expression of ETK in five RCC cell
lines (786-O, 769-P, A-498, ACHN, OS-RC-2) and a nor-
mal renal proximal tubular cell line HK-2 using Western
blot. The results showed that ETK was highly expressed
in all RCC cell lines, whereas it was hardly detected in
the normal renal proximal tubular cell HK-2 (Figure 3).Figure 2 Correlation of ETK expression with overall survival.
Kaplan-Meier curves with univariate analyses (log-rank) between
RCC patients with high ETK expression (dotted line) and low ETK
expression (thick line) (*P<0.05).
Figure 3 Expression of ETK in RCC cell lines. Western blot shows
that ETK is highly expressed in all five RCC cell lines, but hardly
expressed in the normal renal proximal tubular cell HK-2. β-actin is
the loading control.
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and invasion
To examine the functions of ETK, we knocked down
ETK by tranfecting ETK siRNA into RCC cells. We
chose two typical clear cell RCC cell lines 786-O and
769-P for further study. The mRNA and protein expres-
sion of ETK were significantly weaker in ETK siRNA-
transfected cells than that in control siRNA-tranfected
cells (P<0.01) (Figure 4). For 786-O and 769-P respect-
ively, the mRNA expression of ETK was decreased
by 96.7% and 97.3% in the siRNA group compared
with the negative control group (Figure 4A). Western
blot showed that the expression level of ETK was de-
creased by 51.2% in 786-O and 79.8% in 769-P in the
siRNA group compared with the negative control group
(Figure 4B). These results suggested we have succeeded
in knocking down ETK expression.
In order to detect the role of ETK in RCC cell prolifer-
ation, we examined the effect of ETK siRNA on RCCFigure 4 Expression spectrum of ETK in ETK-siRNA-transfected and con
The average ratios of ETK mRNA expression in siRNA group and control group
three parallel experiments. (B) Western blot ETK expression in protein level in
β-actin is the loading control. (**, P<0.01).cell growth. ETK siRNA significantly decreased cell pro-
liferation by 32.4% in 786-O and 28.9% in 769-P at 48 h
compared with the negative control group (P<0.01)
(Figure 5A). And we used flow cytometry to reveal
the effect of ETK on RCC cell apoptosis. ETK siRNA
can promote cell apoptosis (Figure 5B). We used trans-
well assay to assess cell migration and invasion. The
number of migrating cells was significantly decreased in
ETK siRNA group compared with control siRNA group
(30.0 ± 3.7 vs. 113.8 ± 3.3 in 786-O and 15.8 ± 2.5 vs.
104.8 ± 6.0 in 769-P, respectively) (P<0.01) (Figure 5C).
The number of invading cells was significantly decreased
in ETK siRNA group compared with control siRNA
group (9.8 ± 1.0 vs. 30.5 ± 2.1 in 786-O and 7.3 ± 1.3 vs.
37.0 ± 7.9 in 769-P, respectively) (P<0.01) (Figure 5D).
Our data implied that ETK knockdown inhibited cell mi-
gration and invasion in vitro.
ETK knockdown regulates VEGF and STAT3 expression
in RCC
To explore the relationship between VEGF, STAT3 and
ETK, we examined the expression of VEGF, STAT3 and p-
STAT3 using Western blot after downregulating ETK. As
shown in Figure 6, the expression of VEGF and p-STAT3
were decreased, especially the expression of p-STAT3
(P<0.01). The unactivated STAT3 protein meanwhile
remained invariable (P>0.05). The expression of VEGF has
changed but not of STAT3. Only STAT3s activity was al-
tered as indicated by the expression of p-STAT3, whereas
the expression of STAT3 remained unchanged.trol-siRNA-tranfected RCC cells (786-O and 769-P). (A) real-time PCR
. Expression intensity of ETK was normalized by β-actin. Data were from
siRNA group and control group. Protein concentrations were 8 μg/ml.
Figure 5 Effects of ETK on cell proliferation, apoptosis, migration and invasion of RCC cells 786-O and 769-P. Comparing ETK siRNA
group with negative control siRNA group, (A) Cell proliferation was significantly inhibited after ETK siRNA transfection at 48 h. (B) Flow cytometry
indicated that cell apoptosis increased after ETK siRNA transfection at 48 h. (C) Cell migration was significantly inhibited after ETK siRNA
transfection at 36 h. (D) Transwell matrigel invasion assay showed a significant decrease of invaded cells after ETK siRNA transfection at 48 h.
(**, P<0.01).
Figure 6 Expression of VEGF and STAT3 after ETK knockdown.
Western blot showed that the expression of VEGF and p-STAT3 were
decreased, especially the expression of p-STAT3 (P<0.01). While the
unactivated STAT3 protein remained invariable (P>0.05). Protein
concentrations were 8 μg/ml. β-actin is the loading control.
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In the recent few years, increasing evidences indicates that
ETK is overexpressed in various cancer types, including
prostate cancer, bladder cancer, nasopharyngeal carcin-
oma, lung cancer and breast cancer [18,22-25]. In this
study, we evaluated the expression and role of ETK in
RCC. Our results also showed that ETK was overex-
pressed in RCC tissues when compared with that in nor-
mal renal tissues. Furthermore, immunostaining data
indicated that the expression level of ETK was closely cor-
related with clinical stage, histological grade and metasta-
sis of the RCC. In addition, we also found that patients
with higher ETK expression had shorter overall survival
time than those with lower ETK expression. ETK may po-
tentially be used as a prognostic factor for RCC patients.
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cesses, including cell proliferation, apoptosis, migration,
invasion, differentiation and chemo-resistance [26-28].
We found that ETK was highly expressed in all five RCC
cell lines, whereas it was hardly detected in the normal
renal proximal tubular cell HK-2. Frequently elevated
ETK expression in RCC cells suggested that ETK may
play a causal role in disease development and progres-
sion of RCC. We then adopted a strategy of RNA inter-
ference to inhibit ETK expression in two typical clear
cell RCC cell lines 786-O and 769-P. Our results re-
vealed that cell growth, migration and invasion were
inhibited after transfection with ETK siRNA, and cell
apoptosis increased instead. ETK is a major regulatory
molecule in various cell signal pathways; multiple mech-
anisms are involved in ETK-regulated tumorigenesis. Ex-
periments have documented that ETK overexpression
can increase proliferation in mouse prostate epithelium
and result in development of prostatic intraepithelial
neoplasia (PIN) by increasing AKT and STAT3 activity
[21,29]. ETK is an upstream activator of STAT family
and links Src to STAT3 activation [13]. In addition, ETK
can confer drug resistance by interacting with p53 and
inhibiting its nuclear transduction function in prostate
cancer [30]. It has been reported that ETK utilizes both
MEK/ERK and PI3-K/Pak1 signaling pathways in con-
cert to activate VEGF transcription. VEGF is both an
ETK downstream target gene and an ETK upstream
activator, constituting a reciprocal ETK-VEGF autoregu-
latory loop [31]. These mechanisms may explain the
inhibited function of RCC cells by ETK knockdown in
our study. As a result, we hypothesize the VEGF-ETK-
STAT3 loop in RCC. Since ETK knockdown can regulate
the expression of VEGF and STAT3 in RCC, ETK may
play a key role in the VEGF-ETK-STAT3 loop which
might be helpful to the theoretical treatment of RCC.
Like other cancer types, relapse and metastasis are
the main causes of surgery failure in RCC treatment.
RCC is resistant to chemotherapy, radiotherapy and
immunotherapy. Patients with RCC respond to postop-
erative adjuvant therapy at various levels and usually
cannot achieve expected outcomes [32]. For metastatic
or non-resectable RCC, several targeted therapies, such
as multitargeted tyrosine kinase inhibitors (TKIs) and
Temsirolimus, have been approved for the treatment.
They target the VHL-HIF-VEGF and/or mTOR path-
ways. Combination targeted therapy in advanced RCC is
recommended. Even with improvements in survival, dis-
ease progresses in all patients. Resistance ultimately will
occur after a few months or a few years [6,33]. Thus,
the identification and application of novel therapeutic
targets for RCC are urgently needed. The phenotype of
tumor metastasis presents with promotion of cell prolif-
eration, escape from apoptosis, and dysregulation ofcellular adhesion and migration. The invasion of cancer
cells to surrounding tissues and spreading to distal sites
rely on cell migration ability [34]. In the present study,
we found that ETK was highly expressed in about 90%
of the advanced RCC patients. We stated that ETK ex-
pression was associated with high stage, bad differenti-
ation level, and metastasis of RCC and higher levels of
ETK expression were associated with shorter survival
time. After silencing ETK by RNAi in vitro, the migra-
tion and invasion of RCC cells were significantly inhib-
ited, suggesting that ETK may be one of the potential
treatment targets for RCC.
Conclusions
Our study indicated that the high expression of ETK
could promote the carcinogenesis and progression of
RCC and result in a poor overall survival. ETK may be
involved in the VEGF-ETK-STAT3 loop and served as a
potential therapeutic target for RCC, which warrants
verification in further studies.
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